Skip to content
About
Thought Leadership
Careers
Schedule a Demo
Menu
About
Thought Leadership
Careers
Schedule a Demo
Newsroom
Selected Publications
Value in Health. 2021; 24(2): pp. 244-249
“Health Technology Assessment with Diminishing Returns to Health: The Generalized Risk-Adjusted Cost Effectiveness (GRACE) Approach.”
A novel and mathematically rigorous framework for calculating cost-effectiveness when outcomes are uncertain and patients care about risk.
Read More
European Journal of Health Economics. 2021
“A Guide to Extending and Implementing Generalized Risk-Adjusted Cost-Effectiveness (GRACE).”
A presentation of generalized risk-adjusted cost-effectiveness (GRACE), an improvement upon traditional cost-effectiveness useful for predicting value of medical technology with uncertain outcomes.
Read More
Statistics in Medicine. 2021; 40(25):5487-5500
“Penalized regression for left-truncated and right-censored survival data.”
Evaluates statistical methods for prediction and validation of survival models with high-dimensional real-world clinicogenomic data.
Read More
hesim: arXiv preprint arXiv:2012.09437 (2021)
“Health Economic Simulation Modeling and Decision Analysis.”
Describes an open source software package,
hesim
, developed by the authors for simulating the value of medical technologies.
Read More
Health Economics. Published online October 7, 2020
“Predicting quantity and quality of life with the Future Elderly Model”
Validation of a pathbreaking microsimulation model that predicts health outcomes for a representative sample of Americans.
Read More
Value in Health, 2017; 20(7): pp. 866-875
“Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.”
A novel statistical approach to estimating real-world effectiveness outcomes from clinical trial efficacy data.
Read More
Leverage software built by a team with world- class scientific, engineering and industry credentials.
Email
Contact EntityRisk today.
Op-Eds
Fortune. 2017
“Innovative Drugs Deserve Innovative Pricing”
Read More
Harvard Business Review. 2015
“Understanding Health Care's Short-Termism Problem”
Read More
Health Affairs Blog. 2012
"When Epidemiology Goes Astray: Valuing Cancer Care In The United States And Europe"
Read More
Health Affairs Blog. 2015
"Moving Beyond Price-Per-Dose In The Pharmaceutical Industry"
Read More
Health Affairs Blog. 2016
"Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement"
Read More
Health Affairs Blog. 2015
"It's Time For Value-Based Payment In Oncology"
Read More
Health Affairs Blog. 2012
"Harnessing The Promise Of Comparative Effectiveness Research"
Read More
Health Affairs Blog. 2018
"The Long Road To Value-Based Payment: The Case of Transcatheter Aortic Valve Replacement"
Read More
The Hill. 2019
"Here's How We Can Control Drug Costs While Spurring Innovation"
Read More
LinkedIn. 2013
"What Health Care Can Learn from Netflix"
Read More
Modern Healthcare. 2015
"Drop Medicaid 'Best Price' Drug Rules In Favor of Value-Based Strategies"
Read More
STAT. 2019
"Accounting for Hope: Using 'Mean Survival Gain' to Price New Cancer Drugs"
Read More
Wall Street Journal. 2017
"Take Me Out to the Pill Game"
Read More
Wall Street Journal. 2019
"Health Care's Killer App: Life Insurance"
Read More
Leverage software built by a team with world- class scientific, engineering and industry credentials.
Name
Email
Phone Number
Tell us more
Contact EntityRisk today.